Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.
| Revenue (Most Recent Fiscal Year) | $9.99M |
| Net Income (Most Recent Fiscal Year) | $-149.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 20.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1801.03% |
| Net Margin (Trailing 12 Months) | -1800.93% |
| Return on Equity (Trailing 12 Months) | -62.35% |
| Return on Assets (Trailing 12 Months) | -49.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.66 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.66 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.78 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.35 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.78 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 93.12M |
| Free Float | 85.41M |
| Market Capitalization | $184.38M |
| Average Volume (Last 20 Days) | 1.04M |
| Beta (Past 60 Months) | 2.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.28% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |